Pentax rejects Ambu's claims of head start
The pandemic has created a market frenzy for single-use bronchoscopes. Pentax Medical denies that Ambu has a head start over its closest international rivals.
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL INGEMANN KROIER PEDERSEN
According to Pentax Medical, the pandemic has accelerated the demand for medical products that can be used without the risk of infection, increasing the competition on the global market for single-use endoscopes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ambu's Q3 ended better than expected
For subscribers
.jpg)
